title: Gene therapy for C-26 colon cancer using heparin-polyethyleneimine nanoparticle-mediated survivin T34A.
abstract: BACKGROUND
  Gene therapy provides a novel method for the prevention and treatment of cancer, but the clinical application of gene therapy is restricted, mainly because of the absence of an efficient and safe gene delivery system. Recently, we developed a novel nonviral gene carrier, ie, heparin-polyethyleneimine (HPEI) nanoparticles for this purpose.
  
  
  RESULTS
  HPEI nanoparticles were used to deliver plasmid-expressing mouse survivin-T34A (ms-T34A) to treat C-26 carcinoma in vitro and in vivo. According to the in vitro studies, HPEI nanoparticles could efficiently transfect the pGFP report gene into C-26 cells, with a transfection efficiency of 30.5% ± 2%. Moreover, HPEI nanoparticle-mediated ms-T34A could efficiently inhibit the proliferation of C-26 cells by induction of apoptosis in vitro. Based on the in vivo studies, HPEI nanoparticles could transfect the Lac-Z report gene into C-26 cells in vivo. Intratumoral injection of HPEI nanoparticle-mediated ms-T34A significantly inhibited growth of subcutaneous C-26 carcinoma in vivo by induction of apoptosis and inhibition of angiogenesis.
  
  
  CONCLUSIONS
  This research suggests that HPEI nanoparticle-mediated ms-T34A may have a promising role in C-26 colon carcinoma therapy.
authors.affiliation: State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Chengdu, People's Republic of China.
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.forename: Xiang
authors.initials: X
authors.lastname: Gao
authors.forename: Ke
authors.initials: K
authors.lastname: Men
authors.forename: Bilan
authors.initials: B
authors.lastname: Wang
authors.forename: Shuang
authors.initials: S
authors.lastname: Zhang
authors.forename: Jinfeng
authors.initials: J
authors.lastname: Qiu
authors.forename: Meijuan
authors.initials: M
authors.lastname: Huang
authors.forename: Maling
authors.initials: M
authors.lastname: Gou
authors.forename: Ning
authors.initials: N
authors.lastname: Huang
authors.forename: Zhiyong
authors.initials: Z
authors.lastname: Qian
authors.forename: Xia
authors.initials: X
authors.lastname: Zhao
authors.forename: Yuquan
authors.initials: Y
authors.lastname: Wei
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000737:chemistry* / Q000494:pharmacology; D017209:Apoptosis / Q000235:genetics; D045744:Cell Line, Tumor; D002470:Cell Survival / Q000235:genetics; D003110:Colonic Neoplasms / Q000235:genetics / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D016503:Drug Delivery Systems / Q000379:methods; D005260:Female; D015316:Genetic Therapy / Q000379:methods*; D006493:Heparin / Q000737:chemistry; D006651:Histocytochemistry; D051034:Inhibitor of Apoptosis Proteins / Q000096:biosynthesis / Q000235:genetics*; D051379:Mice; D008807:Mice, Inbred BALB C; D053758:Nanoparticles / Q000008:administration & dosage / Q000737:chemistry*; D009389:Neovascularization, Pathologic / Q000473:pathology / Q000628:therapy; D011094:Polyethyleneimine / Q000737:chemistry*; D012097:Repressor Proteins / Q000096:biosynthesis / Q000235:genetics*; D000077022:Survivin; D014162:Transfection / Q000379:methods; D023041:Xenograft Model Antitumor Assays
chemical_list: D000970:Antineoplastic Agents; C117749:Birc5 protein, mouse; D051034:Inhibitor of Apoptosis Proteins; D012097:Repressor Proteins; D000077022:Survivin; D011094:Polyethyleneimine; D006493:Heparin
references.citation: Nat Med. 2000 Oct;6(10):1160-6
references.pmid: 11017149
references.citation: Cancer Prev Res (Phila). 2009 Jun;2(6):581-9
references.pmid: 19470789
references.citation: J Control Release. 2010 Jul 14;145(2):102-8
references.pmid: 20381556
references.citation: Int J Pharm. 2001 Oct 23;229(1-2):1-21
references.pmid: 11604253
references.citation: Int J Pharm. 2011 Feb 28;405(1-2):188-95
references.pmid: 21130850
references.citation: J Control Release. 2008 Mar 20;126(3):187-204
references.pmid: 18261822
references.citation: Proc Natl Acad Sci U S A. 2000 Nov 21;97(24):13103-7
references.pmid: 11069302
references.citation: Clin Cancer Res. 2005 Feb 15;11(4):1474-82
references.pmid: 15746049
references.citation: Anal Biochem. 2003 Jul 15;318(2):230-5
references.pmid: 12814626
references.citation: ACS Nano. 2010 Aug 24;4(8):4587-94
references.pmid: 20731441
references.citation: Prog Biophys Mol Biol. 2004 Feb-Apr;84(2-3):279-99
references.pmid: 14769440
references.citation: ACS Nano. 2011 Mar 22;5(3):1877-87
references.pmid: 21322531
references.citation: Clin Cancer Res. 2003 Dec 15;9(17):6310-5
references.pmid: 14695129
references.citation: Cancer Gene Ther. 2011 Jan;18(1):12-9
references.pmid: 20930861
references.citation: Nanoscale. 2011 Apr;3(4):1558-67
references.pmid: 21283869
references.citation: Am J Surg. 2006 Apr;191(4):517-26
references.pmid: 16531147
references.citation: Cancer Res. 2009 Jan 15;69(2):554-64
references.pmid: 19147569
references.citation: Nanoscale. 2011 Mar;3(3):1252-7
references.pmid: 21270989
references.citation: Cancer Res. 2009 Mar 1;69(5):1851-7
references.pmid: 19223544
references.citation: J Cyst Fibros. 2004 Aug;3 Suppl 2:203-12
references.pmid: 15463959
references.citation: Nature. 1998 Dec 10;396(6711):580-4
references.pmid: 9859993
references.citation: Cancer Treat Rev. 2009 Nov;35(7):553-62
references.pmid: 19559538
references.citation: Biomaterials. 2009 Aug;30(23-24):4014-20
references.pmid: 19427690
references.citation: J Exp Clin Cancer Res. 2008 Sep 25;27:46
references.pmid: 18816410
references.citation: J Immunother. 2007 Feb-Mar;30(2):169-79
references.pmid: 17471164
references.citation: Adv Drug Deliv Rev. 2010 Dec 30;62(15):1524-9
references.pmid: 20399239
references.citation: J Control Release. 2007 Nov 20;123(3):181-3
references.pmid: 17935817
references.citation: J Control Release. 2008 Jul 14;129(2):124-7
references.pmid: 18513820
references.citation: Gene Ther. 2009 Dec;16(12):1395-404
references.pmid: 19641532
references.citation: J Pharm Pharm Sci. 2010;13(3):320-35
references.pmid: 21092706
references.citation: Mol Pharm. 2010 Dec 6;7(6):2216-23
references.pmid: 20863081
references.citation: J Cancer Res Clin Oncol. 2011 Jan;137(1):19-28
references.pmid: 20217127
references.citation: Biomaterials. 2010 Jun;31(17):4771-80
references.pmid: 20219242
references.citation: Biomaterials. 2010 Apr;31(10):2912-8
references.pmid: 20047759
references.citation: CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
references.pmid: 21296855
references.citation: Nanoscale. 2011 Apr;3(4):1461-4
references.pmid: 21301705
references.citation: Cancer Res. 2009 Aug 15;69(16):6581-9
references.pmid: 19654295
references.citation: Adv Drug Deliv Rev. 2006 Jul 7;58(4):467-86
references.pmid: 16781003
references.citation: Eur J Pharm Biopharm. 2009 Mar;71(3):475-83
references.pmid: 18955136
references.citation: J Biosci. 2010 Jun;35(2):209-16
references.pmid: 20689177
references.citation: Cancer Sci. 2010 Nov;101(11):2341-50
references.pmid: 20804501
references.citation: Cancer Sci. 2011 Jul;102(7):1403-9
references.pmid: 21564417
references.citation: ACS Nano. 2010 Oct 26;4(10):5573-84
references.pmid: 20839784
references.citation: Biomacromolecules. 2011 Feb 14;12(2):457-65
references.pmid: 21190334
references.citation: Eur J Pharm Biopharm. 2009 Feb;71(2):161-72
references.pmid: 18824097
references.citation: CA Cancer J Clin. 2005 Jan-Feb;55(1):10-30
references.pmid: 15661684
references.citation: ACS Nano. 2010 Feb 23;4(2):1049-59
references.pmid: 20112968
references.citation: Biomaterials. 2008 Aug-Sep;29(24-25):3477-96
references.pmid: 18499247
references.citation: Nat Rev Cancer. 2003 Jan;3(1):46-54
references.pmid: 12509766
references.citation: Nature. 2004 Feb 26;427(6977):779-81
references.pmid: 14985734
references.citation: CA Cancer J Clin. 2008 Mar-Apr;58(2):97-110
references.pmid: 18227410
references.citation: Cell Cycle. 2008 Apr 15;7(8):1020-35
references.pmid: 18414053
references.citation: Am J Pathol. 2000 Feb;156(2):393-8
references.pmid: 10666367
references.citation: Biomaterials. 2004 Aug;25(17):3783-92
references.pmid: 15020154
references.citation: Curr Gene Ther. 2005 Dec;5(6):629-41
references.pmid: 16457652
references.citation: Cancer Res. 2010 Jan 15;70(2):609-20
references.pmid: 20068171